Structure Therapeutics

GPCR · NASDAQ

$22.88+$0.87 (+3.95%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $22.01

GPCR analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 17 analysts

Average $109.36 (+378.0% upside)

Low: $70.70
Now: $22.88
High: $152.25

Upgrades and downgrades

The latest rating actions, newest first

GPCR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Sep 9, 2026	Maintains	Market Outperform	$110.00	47%
Citigroup	Aug 7, 2026	Maintains	Buy	$100.00 → $97.00	36%
Citizens	Aug 7, 2026	Maintains	Market Outperform	$113.00 → $110.00	47%
HC Wainwright & Co.	Jun 11, 2026	Maintains	Buy	$100.00 → $70.00	16%
Canaccord Genuity	Apr 27, 2026	Initiates	Buy	$101.00	44%
HC Wainwright & Co.	Mar 16, 2026	Maintains	Buy	$114.00 → $100.00	16%
HC Wainwright & Co.	Mar 2, 2026	Maintains	Buy	$90.00 → $114.00	16%
Citizens	Feb 27, 2026	Maintains	Market Outperform	$120.00 → $113.00	47%
JP Morgan	Jan 22, 2026	Maintains	Overweight	$65.00 → $105.00	0%
Guggenheim	Jan 20, 2026	Maintains	Buy	$90.00 → $140.00	57%

The case for and against

Updated Oct 14, 2026

Bull case

Structure Therapeutics is attractive fundamentally because aleniglipron is showing durable efficacy and a cleaner safety profile, with up to 16% weight loss at 72 weeks, an 88% overall completion rate in the OLE, and lower nausea, vomiting, and discontinuation rates after slower titration. The start of the Phase 3 ACCOMPLISH trial adds a major clinical milestone, while additional Phase 2 readouts in 2H26 could reinforce the view that the asset can combine meaningful weight loss with improved tolerability and favorable liver safety. Its oral amylin program also looks promising, as ACCG-2671 showed up to 3% weight loss after a single dose, target engagement, dose-proportional PK, and a six-day half-life that supports weekly dosing.

Bear case

Structure Therapeutics is a clinical-stage company whose lead asset, aleniglipron, still faces major execution risk because Phase 2b gains in obesity and diabetes must be reproduced in larger Phase 3 studies before approval. It also operates in a crowded GLP-1 market with more than 20 competitors, including entrenched big pharma products, so aleniglipron needs a clearly differentiated profile and may still require a commercial partner to win share. Financially, the company is expected to keep posting net losses until commercialization and likely through the early launch phase, while additional capital raises could dilute shareholders and the model’s value assumptions remain highly sensitive to clinical, regulatory, and penetration outcomes.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.